MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-07-2023
Chinook Therapeutics Operating Cash Flow 2011-2026 | KDNY
Annual Operating Cash Flow Chinook Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -117 M | -103 M | -55.8 M | -13.6 M | -68.8 M | -88.9 M | -86.1 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -13.6 M | -117 M | -76.2 M |
Quarterly Operating Cash Flow Chinook Therapeutics
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -50.7 M | - | -80.7 M | -55.3 M | -24.7 M | - | -80.2 M | -55.5 M | -28.1 M | - | -14.6 M | -7.21 M | -3.49 M | - | -43.4 M | -27.6 M | -11.2 M | - | -67.7 M | -44.9 M | -20.6 M | - | -64.6 M | -44.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -3.49 M | -80.7 M | -40.3 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Coherus BioSciences
CHRS
|
-139 M | $ 1.93 | 6.04 % | $ 182 M |  USA |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Editas Medicine
EDIT
|
-165 M | $ 2.32 | 16.0 % | $ 191 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-64.5 M | $ 9.55 | 19.23 % | $ 41.3 M | USA |
 |
MacroGenics
MGNX
|
-81 M | $ 2.36 | 5.83 % | $ 146 M | USA |
 |
AbCellera Biologics
ABCL
|
-131 M | $ 3.52 | 2.03 % | $ 1.05 B |  Canada |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
ADC Therapeutics SA
ADCT
|
-233 M | $ 4.23 | 2.92 % | $ 105 M |  Schweiz |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
AlloVir
ALVR
|
-67.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.59 | 4.66 % | $ 8.64 B |  Australia |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-17.1 M | $ 3.05 | 3.74 % | $ 1.17 M | USA |
 |
Actinium Pharmaceuticals
ATNM
|
-33.1 M | $ 1.2 | - | $ 36.1 M | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
AIkido Pharma
AIKI
|
-15.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Alkermes plc
ALKS
|
521 M | $ 28.45 | -0.63 % | $ 4.69 B |  Irlanda |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Abeona Therapeutics
ABEO
|
-37 M | $ 5.16 | 6.39 % | $ 110 M | USA |
 |
Aileron Therapeutics
ALRN
|
-22.3 M | - | 10.36 % | $ 9.8 M | USA |
 |
Evogene Ltd.
EVGN
|
-24.7 M | $ 0.76 | -0.36 % | $ 27.9 M |  Israel |
 |
Annovis Bio
ANVS
|
-40 M | $ 2.57 | 3.21 % | $ 23.2 M | USA |
 |
Applied Therapeutics
APLT
|
-55.2 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
-36 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Arena Pharmaceuticals
ARNA
|
-452 M | - | -6.81 % | $ 3.04 B | USA |
 |
Blueprint Medicines Corporation
BPMC
|
-193 M | - | - | $ 8.14 B | USA |